<qa>  What is the main cause of uremia and dialysis?Patients with ESRD have a high incidence of acute phase inflammation. Studies have shown that C-reactive Protein CRP and interleukin-6 IL-6 are excellent biomarkers for inflammation, and high levels are predictive of cardiovascular morbidity and mortality in this population. Both uremia and the dialysis process itself contribute to this inflammatory state. It is our hypothesis that paricalcitol therapy decreases the biomarkers of inflammation which may have implications for future studies of morbidity and mortality in this population. 